Who
Anne Nagengast Johnson
Chief Accounting Officer
Company insider
Files Form 4 as: Chief Accounting Officer, AtaiBeckley; Chief Financial Officer, ATAI Life Sciences.
In numbers
- Trades disclosed
- 34
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $96K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 13 Mar 2024
- Last trade
- 11 Sep 2026
- Last filed
- 11 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyBiotechnology | SEC FORM 4 Code D | —140,045 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —326,416 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —200,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —326,416 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —200,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —71,620 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —500,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —550,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —757,915 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —525,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —117,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —71,620 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —500,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —550,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —757,915 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —525,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —117,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyBiotechnology | SEC FORM 4 Code D | —140,045 | filing |
| 30 Jan 2026filed 3 Feb 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code A | —525,000 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code A | —117,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.